CVMP opinions on veterinary medicinal products

The Committee adopted a positive opinion, in exceptional circumstances, for a marketing authorisation for Vaxxinact H5 (Avian influenza vaccine (subunit recombinant)) intended for the following indications associated with highly pathogenic avian influenza (HPAI) serotype 5, including the circulating clade 2.3.4.4b:

• active immunisation to prevent mortality, clinical signs and to reduce viral excretion in chickens and mulard ducks;
• to reduce mortality, clinical signs and viral excretion in muscovy ducks and turkeys;
• to reduce viral excretion in pekin ducks.

The Committee adopted a positive opinion for a marketing authorisation for Ecovaxxin MS (Mycoplasma synoviae vaccine) for the active immunisation of future layer and future breeder chickens from 4 weeks of age to reduce air sac lesions, foot pad lesions (synovitis), ovarian regressions and egg production losses caused by Mycoplasma synoviae infections.

The Committee adopted a…